Stock listing
BOATS:GOSS Gossamer Bio, Inc. Stock
US listing (BOATS) of Gossamer Bio, Inc. · home listing NASDAQ:GOSS
Follow Gossamer Bio, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:GOSS
$10.38 USD -0.31 (-2.9%)
Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:GOSS
- Day range
- $10.19 – $10.74 USDOct 30, 2026
- Volume
- 179,363 sharesOct 30, 2026
- Market cap
- $63.49M USDAt the close on Oct 30, 2026 · price × 6.12M shares outstanding
- 52-week range
- $8.30 – $309.60 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $1.70M USDMedian day 168,216 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GOSS · Home | $10.38 USD | -0.31 (-2.9%) | 179,363 | $10.56 | $10.74 | $10.19 | $10.69 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:GOSS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $10.38 | -0.31 | -2.9% | $10.56 | $10.74 | $10.19 | 179,363 | |
| $10.69 | 0.00 | 0.0% | $10.70 | $11.08 | $10.48 | 105,481 | |
| $10.69 | +0.92 | +9.4% | $9.61 | $10.88 | $9.45 | 185,734 | |
| $9.77 | +0.62 | +6.8% | $9.17 | $9.87 | $9.10 | 137,818 | |
| $9.15 | -0.455 | -4.7% | $9.61 | $9.61 | $8.72 | 250,631 | |
| $9.605 | +0.145 | +1.5% | $9.40 | $9.72 | $9.00 | 144,773 | |
| $9.46 | -0.33 | -3.4% | $9.73 | $9.957 | $9.34 | 190,522 | |
| $9.79 | +0.21 | +2.2% | $9.50 | $10.35 | $9.50 | 218,879 | |
| $9.58 | +1.15 | +13.6% | $8.41 | $9.58 | $8.30 | 212,054 | |
| $8.43 | -0.34 | -3.9% | $8.80 | $8.80 | $8.311 | 179,473 | |
| $8.77 | -0.12 | -1.3% | $8.88 | $8.995 | $8.51 | 171,100 | |
| $8.89 | -0.015 | -0.2% | $8.86 | $9.18 | $8.73 | 197,700 | |
| $8.905 | -0.855 | -8.8% | $9.59 | $9.641 | $8.77 | 360,800 | |
| $9.76 | +0.48 | +5.2% | $9.83 | $10.03 | $9.26 | 478,000 | |
| $9.28 | -0.03 | -0.3% | $9.54 | $9.54 | $8.99 | 155,000 | |
| $9.31 | -0.57 | -5.8% | $9.93 | $10.10 | $9.20 | 289,900 | |
| $9.88 | -0.30 | -2.9% | $10.02 | $10.28 | $9.657 | 196,800 | |
| $10.18 | -0.60 | -5.6% | $10.38 | $10.66 | $9.774 | 280,600 | |
| $10.78 | +0.13 | +1.2% | $10.77 | $10.93 | $10.50 | 196,600 | |
| $10.65 | -0.06 | -0.6% | $10.70 | $10.99 | $10.00 | 390,900 | |
| $10.71 | -0.22 | -2.0% | $11.19 | $11.19 | $10.19 | 235,000 | |
| $10.93 | -0.92 | -7.8% | $11.63 | $12.14 | $10.80 | 351,800 | |
| $11.85 | +0.27 | +2.3% | $11.53 | $12.46 | $11.16 | 381,900 | |
| $11.58 | +0.06 | +0.5% | $11.68 | $11.85 | $11.21 | 384,000 | |
| $11.52 | +0.58 | +5.3% | $10.46 | $11.85 | $10.33 | 516,400 | |
| $10.94 | +0.01 | +0.1% | $10.93 | $11.01 | $10.22 | 426,600 | |
| $10.93 | -0.06 | -0.5% | $10.76 | $11.68 | $10.75 | 236,100 | |
| $10.99 | -0.70 | -6.0% | $11.69 | $11.97 | $10.03 | 453,800 | |
| $11.69 | +0.41 | +3.6% | $11.48 | $12.31 | $11.35 | 195,600 | |
| $11.28 | +0.55 | +5.1% | $11.60 | $11.94 | $10.91 | 258,800 | |
| $10.73 | -1.21 | -10.1% | $12.00 | $12.49 | $10.67 | 530,100 | |
| $11.94 | +0.98 | +8.9% | $11.78 | $12.45 | $11.28 | 267,700 | |
| $10.96 | +0.58 | +5.6% | $10.77 | $11.24 | $9.961 | 271,200 | |
| $10.38 | -0.32 | -3.0% | $10.61 | $10.97 | $10.12 | 220,300 | |
| $10.70 | -0.03 | -0.3% | $10.95 | $11.08 | $10.07 | 325,900 | |
| $10.73 | -0.63 | -5.5% | $12.48 | $12.52 | $10.47 | 472,300 | |
| $11.36 | -1.44 | -11.3% | $12.24 | $12.56 | $11.20 | 165,331 | |
| $12.80 | -1.60 | -11.1% | $12.00 | $13.76 | $12.00 | 296,181 | |
| $14.40 | +0.40 | +2.9% | $13.76 | $14.72 | $13.44 | 1,081 | |
| $14.00 | -0.08 | -0.6% | $13.76 | $14.48 | $13.44 | 1,265 | |
| $14.08 | +0.24 | +1.7% | $13.84 | $14.08 | $13.12 | 895 | |
| $13.84 | +0.48 | +3.6% | $13.28 | $13.84 | $12.88 | 900 | |
| $13.36 | -0.24 | -1.8% | $13.20 | $13.84 | $12.80 | 1,144 | |
| $13.60 | 0.00 | 0.0% | $13.68 | $14.40 | $13.44 | 1,586 | |
| $13.60 | 0.00 | 0.0% | $13.76 | $13.84 | $13.12 | 1,238 | |
| $13.60 | -0.32 | -2.3% | $14.08 | $14.24 | $13.04 | 2,413 | |
| $13.92 | -2.48 | -15.1% | $15.92 | $16.16 | $13.60 | 4,555 | |
| $16.40 | +2.40 | +17.1% | $14.40 | $17.12 | $13.44 | 7,431 | |
| $14.00 | +1.60 | +12.9% | $12.00 | $14.96 | $11.68 | 7,361 | |
| $12.40 | -0.24 | -1.9% | $13.60 | $13.60 | $11.60 | 20,524 | |
| $12.64 | +0.08 | +0.6% | $12.64 | $13.12 | $12.08 | 1,052 | |
| $12.56 | +1.12 | +9.8% | $12.00 | $12.72 | $11.36 | 1,080 | |
| $11.44 | +0.24 | +2.1% | $11.20 | $11.84 | $11.04 | 1,061 | |
| $11.20 | -1.12 | -9.1% | $12.40 | $12.48 | $11.20 | 3,759 | |
| $12.32 | -1.28 | -9.4% | $13.60 | $13.60 | $12.24 | 2,165 | |
| $13.60 | -0.64 | -4.5% | $14.08 | $14.16 | $13.20 | 1,953 | |
| $14.24 | -0.32 | -2.2% | $14.64 | $14.88 | $13.84 | 833 | |
| $14.56 | +0.48 | +3.4% | $14.40 | $14.88 | $13.92 | 1,658 | |
| $14.08 | -0.16 | -1.1% | $14.40 | $14.40 | $13.52 | 2,682 | |
| $14.24 | 0.00 | 0.0% | $14.40 | $14.56 | $13.84 | 1,709 | |
| $14.24 | 0.00 | 0.0% | $14.16 | $14.56 | $13.76 | 1,286 | |
| $14.24 | -0.32 | -2.2% | $14.96 | $14.96 | $14.00 | 1,251 | |
| $14.56 | +0.64 | +4.6% | $13.60 | $14.72 | $13.60 | 2,306 | |
| $13.92 | +0.32 | +2.4% | $13.60 | $14.16 | $12.80 | 2,766 | |
| $13.60 | -0.64 | -4.5% | $14.16 | $14.64 | $13.20 | 4,003 | |
| $14.24 | -2.32 | -14.0% | $16.32 | $16.40 | $13.44 | 4,788 |
- Ticker
- BOATS:GOSS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Sep 23, 2026
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Latest earnings call · May 18, 2026
Gossamer Bio (NASDAQ:GOSS) Q1 2026 Earnings Call
Replay and transcript
Latest deck · May 18, 2026
Q1 2026 Earnings Presentation
Earnings · 21 slides
Calls
Replays
Gossamer Bio (NASDAQ:GOSS) Q1 2026 Earnings Call
Mon, May 18, 2026 · 8:00 AM ET
Watch TranscriptGossamer Bio (NASDAQ:GOSS) Q1 2025 Earnings Call
Thu, May 15, 2025 · 4:30 PM ET
Watch TranscriptGossamer Bio (NASDAQ:GOSS) Q4 2021 Earnings Call
Thu, Mar 03, 2022 · 4:30 PM ET
Watch Transcript
Latest news
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Sep 23, 2026
Closed $10.93 (-0.5%) on Sep 24, 2026
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Sep 16, 2026
Closed $11.94 (+8.9%) on Sep 17, 2026
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Sep 11, 2026
Closed $10.73 (-5.5%) on Sep 11, 2026
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Sep 9, 2026
Closed $12.80 (-11.1%) on Sep 9, 2026
Gossamer Bio to Present at Cantor Global Healthcare Conference
Sep 4, 2026
Closed $14.00 (-0.6%) on Sep 4, 2026
Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval
Aug 21, 2026
Closed $12.40 (-1.9%) on Aug 21, 2026
Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026
Closed $12.32 (-9.4%) on Aug 14, 2026
Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update
Jul 27, 2026
Closed $15.92 (+46.3%) on Jul 27, 2026
Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
Jul 1, 2026
Closed $13.44 (+1.8%) on Jul 1, 2026
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
Jun 17, 2026
Closed $14.32 (+6.5%) on Jun 17, 2026
Financings
Private placement of pre-funded warrants and FDA approval warrants
Aug 21, 2026
Announced: up to US$250M · US$0.1399 a share · Warrants at US$0.187 · Leerink Partners +1
Dealers: Leerink Partners (co-lead), Cantor (co-lead)
Buyers: EcoR1 Capital; 683 Capital Partners, LP; RA Capital Management; Coastlands Capital; Samsara BioCapital; Rock Springs Capital
Use of proceeds: Advance clinical development and potential commercialization of seralutinib in PAH and PH-ILD, general corporate purposes and working capital
Decks
Q1 2026 Earnings Presentation
Earnings · 21 slides · May 18, 2026
Technical Presentation (February 2026)
Technical · 27 slides · Feb 23, 2026
Q1 2025 Earnings Presentation
Earnings · 43 slides · May 15, 2025
Corporate Update (July 2023)
Corporate update · 33 slides · Jul 20, 2023
Gossamer Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 21 in the last 12 months · 109 in all · newest Sep 23, 2026 · oldest 2019
- Calls
- 7 calls with a replay · 7 with a transcript · latest May 18, 2026
- Decks
- 10 decks · latest May 18, 2026
Where Gossamer Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GOSS · Home listing | NASDAQ | United States | USD |
| gettex:4GB | gettex | Germany | EUR |
| LS Exchange:A2PCBS | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PCBS | Lang & Schwarz | Germany | EUR |
| BOATS:GOSS · This page | BOATS | United States | USD |
| Tradegate:4GB | Tradegate | Germany | EUR |
| Dusseldorf:4GB | Dusseldorf | Germany | EUR |
| Frankfurt:4GB | Frankfurt | Germany | EUR |
| Munich:4GB | Munich | Germany | EUR |
| Stuttgart:4GB | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Gossamer Bio, Inc.